Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Erik Eways

Interventional Cardiology Mobile, AL Medical Doctor

NPI 1043266919 CMS profile 1246752

6701 Airport Blvd, Suite D-330, Mobile, AL 36608

Open in the dashboard

General payments

$954

26 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erik Eways of Mobile, AL is reported in the CMS Open Payments database as having received $954 across 26 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 12th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $126 6
2024 General $23 1
2023 General $73 4
2022 General $227 7
2021 General $26 1
2020 General $219 3
2019 General $259 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erik Eways
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Erik Eways were reported at $126. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Erik Eways Interventional Cardiology median Middle half National median
2019 $259 $1,097 $329–$3,048 $163
2020 $219 $473 $161–$1,480 $114
2021 $26 $677 $233–$1,827 $132
2022 $227 $978 $333–$2,724 $149
2023 $73 $1,136 $382–$2,986 $160
2024 $23 $1,181 $395–$3,326 $164
2025 $126 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $432 4 payments
  2. Biotronik Inc. $137 1 payment
  3. Abbott Laboratories $81 3 payments
  4. Amgen Inc. $67 4 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $59 3 payments
  6. Merck Sharp & Dohme Corporation $50 3 payments
  7. Scpharmaceuticals Inc. $35 2 payments
  8. Medtronic, Inc. $23 1 payment
  9. Kiniksa Pharmaceuticals, Ltd. $16 1 payment
  10. Amarin Pharma Inc. $15 1 payment
  11. Other $39 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $954 26 payments
Products named General payments · program years 2019–2025
  1. Resolute $347 3 payments
  2. Orsiro Mission $137 1 payment
  3. CoreValve Evolut $84 1 payment
  4. Repatha $67 4 payments
  5. JARDIANCE $59 3 payments
  6. VERQUVO $50 3 payments
  7. FUROSCIX $35 2 payments
  8. Corlanor $32 2 payments
  9. Diamondback Coronary $30 1 payment
  10. MitraClip System $26 1 payment
  11. Other $119 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,452

Median for Interventional Cardiology: 2,236

Drug cost

$378,979

Median for Interventional Cardiology: $380,412

Branded share of claims

22.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 251 $204,921
Entresto Sacubitril/Valsartan Brand 65 $87,197
Xarelto Rivaroxaban Brand 66 $59,796
Carvedilol Generic 338 $2,885
Atorvastatin Calcium Generic 197 $2,300
Losartan Potassium Generic 190 $2,267
Verapamil Sr Verapamil Hcl Brand 18 $2,225
Midodrine Hcl Generic 16 $2,136
Metoprolol Succinate Generic 162 $1,874
Hydralazine Hcl Generic 78 $1,305

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$168,134

Of which drugs: $473

Medicare patients

711

Average age 75

Services billed

1,890

364 women, 347 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 72%
Heart failure 50%
Arthritis 47%
Diabetes 46%
Atrial fibrillation 44%
Chronic kidney disease 42%
COPD 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 23 92 $473

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record